Valneva SE (VALN) Consolidated Net Income (2021 - 2026)
Valneva SE's (VALN) quarterly Consolidated Net Income came in at -$35.6 million in Q1 2026, down 438.88% year-on-year from $10.5 million in Q1 2025, and up 38.9% quarter-over-quarter from -$58.3 million in Q4 2025.
Valneva SE (VALN) Consolidated Net Income (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Consolidated Net Income across 6 years of filings, most recently posting -$35.6 million for Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$35.6 million, down 438.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$162.3 million (down 95.09% YoY), and the FY2025 annual result was -$134.1 million, down 921.57% from the prior year.
- Consolidated Net Income came in at -$35.6 million for Q1 2026 at Valneva SE, up from -$58.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $72.8 million in Q3 2022 to a low of -$151.4 million in Q2 2022.
- The 5-year median for Consolidated Net Income is -$28.1 million (2022), against an average of -$26.3 million.
- Across the five-year window, Consolidated Net Income surged 424.72% in 2024 and tumbled 460.17% in 2025, its largest moves.
- Valneva SE's Consolidated Net Income stood at -$49.5 million in 2022, then surged by 34.91% to -$32.2 million in 2023, then fell by 22.85% to -$39.6 million in 2024, then tumbled by 47.25% to -$58.3 million in 2025, then jumped by 38.9% to -$35.6 million in 2026.
- The last three Consolidated Net Income figures came in at -$35.6 million (Q1 2026), -$58.3 million (Q4 2025), and -$54.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -35.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.62 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -54.74 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Mar 31, 2025 | -6.61 Mn |
| Dec 31, 2024 | -39.59 Mn |
| Sep 30, 2024 | -9.77 Mn |
| Jun 30, 2024 | -27.21 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | -32.23 Mn |
| Sep 30, 2023 | -31.43 Mn |
| Jun 30, 2023 | -26.39 Mn |
| Mar 31, 2023 | -19.71 Mn |
| Dec 31, 2022 | -49.51 Mn |
| Sep 30, 2022 | 72.80 Mn |
| Jun 30, 2022 | -151.43 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 193.58 Mn |
| Sep 30, 2021 | -185.83 Mn |
| Jun 30, 2021 | -68.19 Mn |